Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 First results on the DCVax phase III trial: raising more questions than providing answers.

Literature DB >> 30137551

First results on the DCVax phase III trial: raising more questions than providing answers.

Wolfgang Wick¹, Martin J van den Bent².

Abstract

Entities: Chemical

Mesh：

Substances：
Cancer Vaccines

Year: 2018 PMID： 30137551 PMCID： PMC6120355 DOI： 10.1093/neuonc/noy125

Source DB: PubMed Journal: Neuro Oncol ISSN： 1522-8517 Impact factor: 12.300

× No keyword cloud information.

4 in total

1. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

Authors: Michael Weller; Nicholas Butowski; David D Tran; Lawrence D Recht; Michael Lim; Hal Hirte; Lynn Ashby; Laszlo Mechtler; Samuel A Goldlust; Fabio Iwamoto; Jan Drappatz; Donald M O'Rourke; Mark Wong; Mark G Hamilton; Gaetano Finocchiaro; James Perry; Wolfgang Wick; Jennifer Green; Yi He; Christopher D Turner; Michael J Yellin; Tibor Keler; Thomas A Davis; Roger Stupp; John H Sampson
Journal: Lancet Oncol Date: 2017-08-23 Impact factor: 41.316

2. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

Authors: Mark R Gilbert; Meihua Wang; Kenneth D Aldape; Roger Stupp; Monika E Hegi; Kurt A Jaeckle; Terri S Armstrong; Jeffrey S Wefel; Minhee Won; Deborah T Blumenthal; Anita Mahajan; Christopher J Schultz; Sara Erridge; Brigitta Baumert; Kristen I Hopkins; Tzahala Tzuk-Shina; Paul D Brown; Arnab Chakravarti; Walter J Curran; Minesh P Mehta
Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544

3. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Authors: Roger Stupp; Sophie Taillibert; Andrew Kanner; William Read; David Steinberg; Benoit Lhermitte; Steven Toms; Ahmed Idbaih; Manmeet S. Ahluwalia; Karen Fink; Francesco Di Meco; Frank Lieberman; Jay-Jiguang Zhu; Giuseppe Stragliotto; David Tran; Steven Brem; Andreas Hottinger; Eilon D. Kirson; Gitit Lavy-Shahaf; Uri Weinberg; Chae-Yong Kim; Sun-Ha Paek; Garth Nicholas; Jordi Bruna; Hal Hirte; Michael Weller; Yoram Palti; Monika E. Hegi; Zvi Ram
Journal: JAMA Date: 2017-12-19 Impact factor: 56.272

4. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Authors: Linda M Liau; Keyoumars Ashkan; David D Tran; Jian L Campian; John E Trusheim; Charles S Cobbs; Jason A Heth; Michael Salacz; Sarah Taylor; Stacy D D'Andre; Fabio M Iwamoto; Edward J Dropcho; Yaron A Moshel; Kevin A Walter; Clement P Pillainayagam; Robert Aiken; Rekha Chaudhary; Samuel A Goldlust; Daniela A Bota; Paul Duic; Jai Grewal; Heinrich Elinzano; Steven A Toms; Kevin O Lillehei; Tom Mikkelsen; Tobias Walbert; Steven R Abram; Andrew J Brenner; Steven Brem; Matthew G Ewend; Simon Khagi; Jana Portnow; Lyndon J Kim; William G Loudon; Reid C Thompson; David E Avigan; Karen L Fink; Francois J Geoffroy; Scott Lindhorst; Jose Lutzky; Andrew E Sloan; Gabriele Schackert; Dietmar Krex; Hans-Jorg Meisel; Julian Wu; Raphael P Davis; Christopher Duma; Arnold B Etame; David Mathieu; Santosh Kesari; David Piccioni; Manfred Westphal; David S Baskin; Pamela Z New; Michel Lacroix; Sven-Axel May; Timothy J Pluard; Victor Tse; Richard M Green; John L Villano; Michael Pearlman; Kevin Petrecca; Michael Schulder; Lynne P Taylor; Anthony E Maida; Robert M Prins; Timothy F Cloughesy; Paul Mulholland; Marnix L Bosch
Journal: J Transl Med Date: 2018-05-29 Impact factor: 5.531

4 in total

1. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.

Authors: Daniel I Hoffman; Kalil G Abdullah; Makayla McCoskey; Zev A Binder; Donald M O'Rourke; Arati S Desai; MacLean P Nasrallah; Ashkan Bigdeli; Jennifer J D Morrissette; Steven Brem; Stephen J Bagley
Journal: J Neurooncol Date: 2019-09-21 Impact factor: 4.130

First results on the DCVax phase III trial: raising more questions than providing answers.

1. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

2. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

3. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

4. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

1. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.

Review 2. Current Advances in Immunotherapy for Glioblastoma.

Review 3. Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations.

Review 4. Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies.